Biomarkers of Ovarian Reserve Don't Indicate Infertility

Share this content:
Biomarkers of Ovarian Reserve Don't Indicate Infertility
Biomarkers of Ovarian Reserve Don't Indicate Infertility

TUESDAY, Oct. 10, 2017 (HealthDay News) -- Biomarkers indicating diminished ovarian reserve versus normal ovarian reserve are not associated with reduced fertility among women aged 30 to 44 years without a history of infertility who have been trying to conceive for three months or less, according to a study published online Oct. 10 in the Journal of the American Medical Association.

Anne Z. Steiner, M.D., M.P.H., from the University of North Carolina in Chapel Hill, and colleagues conducted a prospective time-to-pregnancy cohort study involving 750 women aged 30 to 44 years without a history of infertility who had been trying to conceive for three months or less.

The researchers found that the predicted probability of conceiving was not significantly lower for women with low antimüllerian hormone values compared to women with normal values by six cycles of attempt (65 versus 62 percent) or by 12 cycles of attempt (84 versus 75 percent) after adjustment for confounding variables. The predicted probability of conceiving was not significantly different for women with high serum follicle-stimulating hormone versus women with normal values after six cycles of attempt (63 versus 62 percent) or after 12 cycles of attempt (82 versus 75 percent); similar results were seen for high urinary follicle-stimulating hormone values.

"These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antimüllerian hormone levels to assess natural fertility for women with these characteristics," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Extended-Release Naltrexone Promising for Opioid Dependence

Extended-Release Naltrexone Promising for Opioid Dependence

Lower use of heroin, other illicit opioids with extended-release naltrexone in superiority analysis

New Expert Consensus Pathway for Mitral Regurgitation

New Expert Consensus Pathway for Mitral Regurgitation

Etiology, mechanism, severity, indications for treatment should be assessed after MR is identified

Many Dermatology Guideline Authors Get Industry Payments

Many Dermatology Guideline Authors Get Industry Payments

22 of 40 guideline authors receiving payments did not accurately disclose industry relationships

is free, fast, and customized just for you!

Already a member?

Sign In Now »